The heparin concept sector fell 2%, with companies concerned

On August 26th, the heparin concept sector fell by 2%.
of the top five stocks in the
sector were: Hepple at 23.96 yuan, down 4.20%, Fengyuan Pharmaceuticals at 10.18 yuan, down 3.78%; Chang Yampomharma reported 7.05 yuan, down 3.29 percent, Jingfeng Pharmaceuticals reported 5.31 yuan, down 2.93 percent, and Shuangli Pharmaceuticals reported 12.61 yuan, down 2.78 percent.
recent years, the heparin concept sector has received market attention.
, the relevant listed companies have also disclosed the first half of 2020 earnings report.
, Jianyou shares for the domestic heparin API production of leading enterprises, but also a small number of domestic through the FDA and the European Union EDQM certification of heparin API manufacturers.
company's heparin terminal preparations have developed rapidly in recent years.
that in the past three years, its annual average of 10 product speed declaration, the cumulative number of declared products more than 40.
company has been registered in China 8 approval number, the international market has been approved more than 20 registered approvals, products around cardiovascular, anti-tumor, surgically assisted medication and other sub-areas.
addition, Jianyou shares of Ino heparin injections are also in Europe, South America market has been listed for sale.
first half of 2020, Jianyou shares make full use of the advantages of resources, accurately grasp market opportunities.
, the company achieved operating income of RMB1,396 million and net profit of RMB407 million, up 18.64 percent and 40.67 percent year-on-year, respectively.
revenue growth was mainly due to the rapid growth in preparation sales during the reporting period and the increase in raw material sales.
It is worth mentioning that during the reporting period, the company also has a number of domestic products into the priority review process;
Changshan Pharmaceuticals is one of the few leading enterprises in China that has a complete heparin product industry chain and can simultaneously engage in the research and development, production and sale of heparin crudes, heparin raw materials and heparin preparations.
, the company is one of the few domestic production enterprises with four low molecular weight heparin preparations at the same time.
, low molecular weight heparin calcium injection products are the core products of Changshan Pharmaceuticals.
company's 2020 half-yearly report showed that in the first half of the year, the company achieved operating income of 1.010 billion yuan, up 11.84 percent year-on-year, and net profit attributable to shareholders of listed companies was 131 million yuan, up 5.98 percent year-on-year.
sales of preparations, heparin preparations achieved a revenue of $592 million, down 3.57% from a year earlier, and remained the company's main source of profits.
, Changshan Pharmaceuticals' low molecular weight heparin calcium injection sales revenue of 466 million yuan, for ten consecutive years the domestic market ranked first.
that the company's first-half revenue growth is mainly due to higher sales of heparin raw materials.
heparin injection sales and the increase in the average sales price, the company recently responded to investors on the interactive platform, said the company's operating performance in the first half of 2020 to benefit from the increase in sales and average sales prices, rapid growth.
also said that its heparin products in the main market abroad, so the current heparin revenue mainly from abroad, but the company also attaches importance to the domestic market, and constantly increase the domestic market for heparin preparations to open up efforts, while actively introducing new drug types layout of the domestic market, and strive to improve the size of domestic market revenue.
In addition to these enterprises, Chihong Pharmaceuticals recently released its 2020 half-year report showing that in the first half of 2020, the company achieved operating income of 655 million yuan, a decrease of 22.32% YoY, and realized a net profit attributable to shareholders of listed companies of 63.7069 million yuan, a decrease of 63.56 percent YoY.
the first half of the year was mainly affected by the special period, the company's first quarter of domestic and foreign sales business significantly reduced.